
From silent infection to rapid death: Why are some people more vulnerable to COVID-19?
Scientists discover genetic and immunological causes of 15 percent of life-threatening COVID-19 cases

15,000 COVID-19 tests produced by McGill University and the RI-MUHC: a step toward Canadian self-sufficiency
In July 2020, the McGill University Health Centre’s (MUHC's) Department of Clinical...

Protecting lung cancer patients from COVID-19 – and learning from the experience
A study led by Dr. Nathaniel Bourganim tracked changes in treatment plans

New study of therapy options in metastatic melanoma
RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors

Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening

Serious Flaws in Studies Linking COVID-19 and Air Pollution
Studies have yet to prove this link, say Carleton and McGill University epidemiologists

Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations

COVID-19 Q&A on dealing with pandemic fatigue
“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley

New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk
RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study